Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

@inproceedings{Knudsen2016DifferentHV,
  title={Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens},
  author={Niels Peter Hell Knudsen and Anja Weinreich Olsen and Cecilia Buonsanti and Frank Follmann and Yuan Zhang and Rhea N Coler and Christopher B Fox and Andreas Meinke and Ugo D´Oro and Daniele Casini and Alessandra Bonci and Rolf Billeskov and Ennio de Gregorio and Rino Rappuoli and Ali Mohaghegh Harandi and Peter {\O}stergaard Andersen and Else Marie Agger},
  booktitle={Scientific reports},
  year={2016}
}

• Niels Peter Hell Knudsen, Anja Weinreich Olsen, +14 authors Else Marie Agger
• Published in Scientific reports 2016
• DOI:10.1038/srep19570

The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need for novel adjuvants, there are still very few adjuvants in licensed human vaccines. A vast number of adjuvants have been tested pre-clinically using different experimental conditions, rendering it impossible to directly compare their activity. We performed a head-to-head comparison of five different… CONTINUE READING

View on PubMed

BETA

Alternate Sources

Save to Library

Create Alert

Cite